{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:13:27Z","timestamp":1783995207271,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.diabet.2025.101668","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T16:01:34Z","timestamp":1748620894000},"page":"101668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiorenal outcomes and safety of SGLT2 inhibitors in patients with diabetes secondary to disorders of the exocrine pancreas: a nationwide population-based study"],"prefix":"10.1016","volume":"51","author":[{"given":"Kyoung Hwa","family":"Ha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4783-6799","authenticated-orcid":false,"given":"Seung Jin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2025.101668_bib0001","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.2337\/dc22-S002","article-title":"Classification and diagnosis of diabetes: Standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2025.101668_bib0002","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1530\/EJE-20-0974","article-title":"Diagnosis of endocrine disease: diagnosing and classifying diabetes in diseases of the exocrine pancreas","volume":"184","author":"Petrov","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.diabet.2025.101668_bib0003","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.2337\/dc17-0542","article-title":"Incidence, demographics, and clinical characteristics of diabetes of the exocrine pancreas (type 3c): a retrospective cohort study","volume":"40","author":"Woodmansey","year":"2017","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2025.101668_bib0004","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41575-018-0087-5","article-title":"Global epidemiology and holistic prevention of pancreatitis","volume":"16","author":"Petrov","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101668_bib0005","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1080\/07853890.2022.2090601","article-title":"Post-pancreatitis diabetes mellitus: insight on optimal management with nutrition and lifestyle approaches","volume":"54","author":"Singh","year":"2022","journal-title":"Ann Med"},{"key":"10.1016\/j.diabet.2025.101668_bib0006","first-page":"55","article-title":"Ethnic and geographic variations in the incidence of pancreatitis and post-pancreatitis diabetes mellitus in New Zealand: a nationwide population-based study","volume":"130","author":"Pendharkar","year":"2017","journal-title":"N Z Med J"},{"key":"10.1016\/j.diabet.2025.101668_bib0007","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S2468-1253(16)30106-6","article-title":"Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer","volume":"1","author":"Hart","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101668_bib0008","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2337\/dc21-0333","article-title":"Glucose-lowering therapy in patients with postpancreatitis diabetes mellitus: a nationwide population-based cohort study","volume":"44","author":"Viggers","year":"2021","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2025.101668_bib0009","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2337\/dc21-1659","article-title":"Characteristics and clinical course of diabetes of the exocrine pancreas: a nationwide population-based cohort study","volume":"45","author":"Lee","year":"2022","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2025.101668_bib0010","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2337\/dc21-2531","article-title":"Risk of major adverse cardiovascular events, severe hypoglycemia, and all-cause mortality in postpancreatitis diabetes mellitus versus type 2 diabetes: a nationwide population-based cohort study","volume":"45","author":"Olesen","year":"2022","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2025.101668_bib0011","doi-asserted-by":"crossref","first-page":"804","DOI":"10.14309\/ajg.0000000000000225","article-title":"Risk of mortality and hospitalization after post-pancreatitis diabetes mellitus vs type 2 diabetes mellitus: a population-based matched cohort study","volume":"114","author":"Cho","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.diabet.2025.101668_bib0012","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"Pharmacologic Approaches to glycemic treatment: Standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2025.101668_bib0013","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4093\/dmj.2024.0249","article-title":"2023 clinical practice guidelines for diabetes management in Korea: full version recommendation of the Korean diabetes association","volume":"48","author":"Moon","year":"2024","journal-title":"Diab Metab J"},{"key":"10.1016\/j.diabet.2025.101668_bib0014","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s40265-023-01913-5","article-title":"Diabetes of the exocrine pancreas: implications for pharmacological management","volume":"83","author":"Goodarzi","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.diabet.2025.101668_bib0015","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.pan.2013.05.002","article-title":"Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012","volume":"13","author":"Rickels","year":"2013","journal-title":"Pancreatology"},{"key":"10.1016\/j.diabet.2025.101668_bib0016","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000329188","article-title":"Pancreatogenic diabetes: special considerations for management","volume":"11","author":"Cui","year":"2011","journal-title":"Pancreatology"},{"key":"10.1016\/j.diabet.2025.101668_bib0017","first-page":"105","article-title":"Effect of chronic pancreatitis on complications and mortality in dm patients: a 10-year nationwide cohort study","author":"Lin","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2025.101668_bib0018","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: A SMART-C Collaborative Meta-Analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2025.101668_bib0019","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/dom.14261","article-title":"Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a nationwide population-based study","volume":"23","author":"Han","year":"2021","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2025.101668_bib0020","first-page":"799","article-title":"Data resource profile: the national health information database of the national health insurance service in South Korea","volume":"46","author":"Cheol Seong","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.diabet.2025.101668_bib0021","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101668_bib0022","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101668_bib0023","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101668_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/dbi20-0040","article-title":"SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the national kidney foundation","volume":"70","author":"Tuttle","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2025.101668_bib0025","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","article-title":"Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations","volume":"81","author":"Usman","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2025.101668_bib0026","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019918","article-title":"Sodium-glucose cotransporter 2 inhibitors, all-cause mortality, and cardiovascular outcomes in adults with type 2 diabetes: a Bayesian meta-analysis and meta-regression","volume":"10","author":"Odutayo","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.diabet.2025.101668_bib0027","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 Diabetes, 2022. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2025.101668_bib0028","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2337\/dc19-0145","article-title":"Antidiabetic medications and mortality risk in individuals with pancreatic cancer-related diabetes and postpancreatitis diabetes: a nationwide cohort study","volume":"42","author":"Cho","year":"2019","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2025.101668_bib0029","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/MPA.0b013e3181ca3da4","article-title":"Epidemiological study of pancreatic diabetes in Japan in 2005: a nationwide study","volume":"39","author":"Ito","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.diabet.2025.101668_bib0030","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.pan.2020.05.023","article-title":"Comparing diabetes due to diseases of the exocrine pancreas to type 1 and type 2 diabetes using propensity score matching","volume":"20","author":"Lanzinger","year":"2020","journal-title":"Pancreatology"},{"key":"10.1016\/j.diabet.2025.101668_bib0031","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with Ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101668_bib0032","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.2337\/dc17-0792","article-title":"Defects in alpha-cell function in patients with diabetes due to chronic pancreatitis compared with patients with type 2 diabetes and healthy individuals","volume":"40","author":"Mumme","year":"2017","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2025.101668_bib0033","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.4093\/dmj.2024.0036","article-title":"Diabetic ketoacidosis as an effect of sodium-glucose cotransporter 2 inhibitor: real world insights","volume":"48","author":"Baek","year":"2024","journal-title":"Diab Metab J"},{"key":"10.1016\/j.diabet.2025.101668_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow","year":"2023","journal-title":"BMJ Open Diab Res Care"},{"key":"10.1016\/j.diabet.2025.101668_bib0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/2050640616684695","article-title":"United European gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United","volume":"5","author":"Lohr","year":"2017","journal-title":"Eur. Gastroenterol J"},{"key":"10.1016\/j.diabet.2025.101668_bib0036","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M18-3136","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study","volume":"171","author":"Dave","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2025.101668_bib0037","article-title":"SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: a population-based propensity score-matched cohort study","volume":"195","author":"Chan","year":"2023","journal-title":"Diab Res Clin Pr."},{"key":"10.1016\/j.diabet.2025.101668_bib0038","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s13300-024-01613-7","article-title":"Risk of urogenital bacterial infection with sodium-glucose cotransporter-2 inhibitors: a retrospective cohort study using a claims database","volume":"15","author":"Imai","year":"2024","journal-title":"Diab Ther"},{"key":"10.1016\/j.diabet.2025.101668_bib0039","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/dom.14082","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: A multi-site, prevalent new-user cohort study","volume":"22","author":"Fisher","year":"2020","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2025.101668_bib0040","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s11096-022-01476-7","article-title":"SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports","volume":"44","author":"Palapra","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.diabet.2025.101668_bib0041","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/pds.5313","article-title":"An investigation on the association between sodium glucose co-transporter 2 inhibitors use and acute pancreatitis: a VigiBase study","volume":"30","author":"Frent","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.diabet.2025.101668_bib0042","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/pds.4943","article-title":"Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"29","author":"Tang","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.diabet.2025.101668_bib0043","doi-asserted-by":"crossref","first-page":"e5800","DOI":"10.1002\/pds.5800","article-title":"Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: a post-authorization safety study","volume":"33","author":"Fazeli Farsani","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S126236362500062X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S126236362500062X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T22:44:59Z","timestamp":1753310699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S126236362500062X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S126236362500062X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101668","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiorenal outcomes and safety of SGLT2 inhibitors in patients with diabetes secondary to disorders of the exocrine pancreas: a nationwide population-based study","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101668"}}